optima-logo.png
Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD
December 12, 2022 10:08 ET | Opthea Limited
MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
optima-logo.png
Opthea to Present at the FLORetina 2022 Congress
December 06, 2022 06:00 ET | Opthea Limited
MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
optima-logo.png
Opthea to Present at Jefferies London Healthcare Conference
November 10, 2022 06:00 ET | Opthea Limited
MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
optima-logo.png
Opthea Expands Leadership Team with the Appointment of Timothy E. Morris as Chief Financial Officer
October 24, 2022 06:00 ET | Opthea Limited
Key appointment as Opthea progresses Phase 3 registrational trials of OPT-302 for wet AMD MELBOURNE, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical...
optima-logo.png
Opthea Reports Fiscal Year 2022 Financial Results and Corporate Highlights
August 30, 2022 06:00 ET | Opthea Limited
Secured up to US$170m in non-dilutive financing Received commitments for well supported US$90m equity financing; closed first tranche for US$41.9 million Expanded management team and US operations...
optima-logo.png
Opthea Announces Presentation at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
August 16, 2022 07:46 ET | Opthea Limited
MELBOURNE, Australia, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
optima-logo.png
Opthea Successfully Closes Well Supported US$90 Million Equity Financing
August 14, 2022 21:02 ET | Opthea Limited
MELBOURNE, Australia, Aug. 14, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ: OPT) (Opthea), a clinical stage biopharmaceutical company developing novel therapies to treat highly...
optima-logo.png
Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD
August 14, 2022 21:01 ET | Opthea Limited
Carlyle and its life sciences franchise Abingworth, working with their recently formed development company Launch Therapeutics (Launch Tx), to provide non-dilutive financing of up to US$170M,...
optima-logo.png
Opthea To Present at Upcoming Investor Conferences
May 11, 2022 08:00 ET | Opthea Limited
MELBOURNE, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive...
optima-logo.png
Opthea Presentation at The Retina World Congress 2022
May 10, 2022 08:20 ET | Opthea Limited
MELBOURNE, Australia, May 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...